In western countries, prostate cancer is the most common non-dermatological malignant disease in men. An estimated 217730 new cases will have been diagnosed in 2010 in the USA (Jemal A et al., 2010) and 382250 cases were diagnosed in 2008 in Europe (Ferlay J et al., 2010), accounting for 28% and 22% of new non-cutaneous cancer diagnoses, respectively. Bone is one of the most common sites of metastatic disease in patients with cancer, affecting approximately 400,000 patients each year. Nearly 70% of patients with advanced breast or prostate cancer will experience bone lesions; 50% of these patients will develop a secondary skeletal complications which represents a substantial disease and economic burden (Schulman KL & Kohles J, 2007). The pathologic penetration of bone by tumour tissue can lead to numerous skeletal-related events, such as hypercalcemia, fracture, spinal cord compression, and potentially debilitating bone pain (Berruti A et al., 2002). Often these consequences result in the need for radiological and surgical intervention. Along with these therapies, pharmacological management is required to help reduce symptoms, prevent recurrence and further improve patients’ quality of life. Prostate carcinoma is the most common visceral malignancy and the second leading cause of death from cancer in men (Diamond T et al., 2004). Androgen-deprivation therapy (ADT), either alone (as depot gonadotrophin releasing hormone agonist) or in combination with antiandrogens (such as flutamide, bicalutamide, or cyproterone acetate), is recommended treatment for men with metastatic or locally advanced, non-metastatic prostate carcinoma (Fowler JE et al., 2002). Although it has been demonstrated that this form of therapy significantly reduces tumour growth and improves survival beyond 3 years after completion (Bolla M et al., 1997), there is growing concern regarding the negative effects of ADT on the skeleton. Accelerated bone loss, osteoporosis, and a potential for increased. Fracture rates have been reported in men with prostate carcinoma who are receiving ADT. Because many patients who present with prostate carcinoma are elderly and may have